MLB

Hall of Fame second baseman Ryne Sandberg says he has metastatic prostate cancer

Associated Press
By Associated Press
2 Min Read Jan. 22, 2024 | 2 years Ago
Go Ad-Free today

CHICAGO — Hall of Fame second baseman Ryne Sandberg has been diagnosed with metastatic prostate cancer.

The 64-year-old Sandberg said Monday in a release put out by the Baseball Hall of Fame that he has started treatment.

“I am surrounded by my loving wife Margaret, our incredibly supportive family, the best medical care team, and our dear friends,” Sandberg said. “We will continue to be positive, strong, and fight to beat this. Please keep us in your thoughts and prayers during this difficult time for me and my family.”

Sandberg hit .285 with 282 homers, 1,061 RBIs and 344 steals in 16 seasons in the majors. He made his big league debut with Philadelphia in 1981 and appeared in 13 games with the Phillies before he was traded to the Chicago Cubs in January 1982.

Sandberg turned into one of the majors’ best all-around performers with the Cubs. He made 10 All-Star teams and won nine Gold Gloves. He also was the NL MVP in 1984.

He was inducted into Cooperstown in 2005.

“Part of what made Ryne a tremendous talent on the field was his quiet intensity, and we have no doubt he’ll bring the same tenacity to his fight,” Hall of Fame chair Jane Forbes Clark said in a statement.

“During this difficult time, we join Cubs fans in Chicago, and baseball fans everywhere, in sending love and support to Ryne and Margaret and the entire Sandberg family.”

Share

Categories:

Tags:

About the Writers

Sports and Partner News

Push Notifications

Get news alerts first, right in your browser.

Enable Notifications

Content you may have missed

Enjoy TribLIVE, Uninterrupted.

Support our journalism and get an ad-free experience on all your devices.

  • TribLIVE AdFree Monthly

    • Unlimited ad-free articles
    • Pay just $4.99 for your first month
  • TribLIVE AdFree Annually BEST VALUE

    • Unlimited ad-free articles
    • Billed annually, $49.99 for the first year
    • Save 50% on your first year
Get Ad-Free Access Now View other subscription options